🇺🇸 FDA
Pipeline program

nalbuphine HCl ER

TR03ext

Phase 3 small_molecule completed

Quick answer

nalbuphine HCl ER for Prurigo Nodularis is a Phase 3 program (small_molecule) at Trevi Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Trevi Therapeutics
Indication
Prurigo Nodularis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials